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Unavailability and lack of appropriate, effective and safe formulations are common 
problems in paediatric therapeutics. Key factors such as swallowing abilities, 
organoleptic preferences and dosage requirements determine the need of for 
optimization of formulations. 
The provisional Biopharmaceutics Classification System can be used in paediatric 
formulation design as a risk analysis and optimization tool. 
 
The objective of this study was to classify six neglected tropical diseases drugs 
following a provisional paediatric BCS (pBCS) classification adapted to three 
paediatric subpopulations (neonates, infants and children).  
 
Methods 
Albendazole, benznidazole, ivermectin, nifurtimox, praziquantel and proguanil 
were selected from the 5th edition of Model List of Essential Medicines for Children 
from WHO.  
Paediatric drug solubility classification was based on dose number calculation. 
Provisional permeability classification was based on logP comparison versus 
metoprolol logP value, assuming passive diffusion absorption mechanisms and no 
changes in passive membrane permeability between paediatric and adults. pBCS 
classes were estimated for each drug, according to different doses and volumes 
adapted for each age stage and were compared to the adult classification 
 
Results 
All six drugs were classified into provisional pBCS in the three paediatric 
subpopulations. Three drugs maintained the same classification as for adults, 
Ivermectin and Benznidazole changed solubility class from low to high in neonates 
and Proguanil changed from low to high solubility in all age stages.   
 
Conclusion 
Provisional pBCS classification of these six drugs shows potential changes in the 
limiting factors in oral absorption in paediatrics, depending on age stage, 
compared to the adult population. This valuable information will aid the optimise 
paediatric dosing and formulations and can identify bioinequivalence risks when 
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What is already known about this subject? 
 
BCS has demonstrated to be an essential development tool for adult medication 
but its application to paediatric development requires further research in child 
physiology. In the case of neglected diseases the lack of commercial preparation 
worsen this situation and the pharmacist practitioner needs tools for dosing 
decision and compounding. 
 
What this study adds? 
 
This study adds the provisional classification of 6 drugs based in a proposed 
paediatric BCS. The study highlights the knowledge gaps for pediatric BCS 
classification and shows how this classification can be used as a tool for 
pharmaceutical compounding decision. The design of harmonized national 











The World Health Organization (WHO) defines as "Neglected tropical diseases" 
(NTDs) a group of infectious diseases in tropical and subtropical regions spanning 
across 149 countries. The population affected are mainly those living in poverty 
without adequate sanitation and in contact with infectious vectors and animals 
(domestic and livestock)(1). Initially, the NTD term grouped a set of infectious 
diseases caused by helminths, bacteria and protozoa. Today, the list includes more 
than 40 diseases including viral, fungal and ectoparasitic infection pathways(2). 
In usual clinical practice and especially in the field of NTDs, paediatric 
formulations are frequently derived from adult formulations. It is broadly accepted 
that there is a need for development of paediatric formulations(3–5). Paediatric 
patients represent a varying and dynamic population with significant differences 
in ADME processes (absorption, distribution, metabolism and excretion), as 
compared to adult patients(5). Furthermore, children need age-appropriate 
formulations that: a) fit with changes derived from aging and gaining weight, b) 
have acceptable safety and c) are adapted for their growth and ability to take 
medication(3).  
The paediatric population requires galenic preparations different from adults, 
mostly tablets and capsules, which do not allow adjusting the appropriate dose. 
Therefore, proper treatment is hampered due to their special conditions of 
swallowing abilities, organoleptic properties and dosage requirements(6). 
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The Biopharmaceutics Classification System (BCS) is a theoretical scheme that 
categorizes drugs into four classes (Figure 1) considering their solubility and 
permeability(7). Both are fundamental parameters controlling the absorption of 
any drug administered orally(7). The BCS has gained broad acceptance in the 
pharmaceutical industry and has significantly impacted adult drug 
development(5,8). This system, applied to paediatrics, can be an excellent guide 
for the industry and for pharmacists dedicated to compounding and could benefit 
the paediatric population as it allows the identification of drugs that need a specific 
formulation for children at different stages of growth. In addition, BCS improves 
regulatory approval processes in terms of efficiency by contributing to universal 
public health(9). Nevertheless, BCS classification is based on adult data, and cannot 
be extrapolated to children, because of developmental issues. These differences 
suggest the need of a specific paediatric Biopharmaceutics Classification System 
(pBCS). 
Some international programs and initiatives have been launched to improve the 
current situation in drug paediatric development, for instance the European 
Paediatric Formulation Initiative(10) and the US Paediatric Formulation 
Initiative(11). These initiatives have recognized the potential utility of a pBCS for 
pediatric development(5). Professional associations have organized workgroups to 
address the paediatric drug development needs as the “Paediatric Formulations 
Task Force” from the American Association of Pharmaceutical Scientists(6). In the 
area of NTD-related treatments there has been examples of successful projects as 
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 8 
the Paediatric Praziquantel Consortium(12) in which it was developed, by applying 
BCS concepts, a paediatric formulation tablet of praziquantel to combat 
schistosomiasis in children. The “Drugs for Neglected Diseases initiative (DNDi)” is 
another example of a collaborative-non-profit drug research organization that is 
developing new treatments for neglected diseases(13). All these activities are 
aligned with the new regulatory frameworks in EMA and FDA that include the 
requirement of a Pediatric Investigation Plan (PIP) or Pediatric Study Plan (PSP) in 
drugs that could be used in children(14,15).   
Since 2007, the WHO provided the WHO Model List of Essential Medicines for 
Children(16); a core list of minimum medicine needs for a basic health-care 
system, listing the most efficacious, safe and cost-effective medicines for priority 
conditions in children up to 12 years old. From this list, six oral drugs that are used 
to treat NTDs were selected for the present work. In addition, the selected 
compounds are marketed as tablets, which are not suitable for paediatric 
administration. 
The objective was to provisionally classify six NTDs drugs following a proposal of 
pBCS adapted to three paediatric subpopulations, namely neonates, infants and 
children. Albendazole, benznidazole, ivermectin, nifurtimox, praziquantel and 
proguanil (Figure 2) were selected as they meet the above requirements and 
because there are not clear recommendations about their dosage, safety, efficacy 
and formulation for the different paediatric stages. In addition, three of them 
(albendazole, benznidazole and nifurtimox) were listed on the report “Best 
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Paediatric Solubility Classification 
 
Paediatric drug solubility classification was determined via paediatric dose 







where M0p is the paediatric highest dose strength (in milligrams), V0p is the water 
volume taken with a dose (in millilitres), and Cs is de solubility in milligrams per 
millilitre. 
A paediatric dose number required paediatric dose as well as paediatric reference 
volume, consequently there would not be a single pBCS classification boundaries 
as several subpopulations exist within the paediatric population. 
A paediatric reference volume (V0p) was calculated for each of the three 
subpopulations: neonates (0-1 month), infants (1-24 months) and children (2-12 
years). For each subpopulation, the volume was calculated based on body surface 
area (BSA), relative to the adult volume of 250 mL(19) and adult BSA of 1.73 m2. 
Subpopulation BSA was calculated(20) from: 
BSA (m2) =
�Height(cm) ×  Weight(kg)
60
 




where height and weight were taken to be the 50th percentile of boy values in the 
WHO growth charts for ages 0.5 months and 12.5 months(21) and Center of 
Diseases Control and Prevention (CDC) charts for age 7 years(22).  
 
M0p for each subpopulation was obtained from the WHO Model Prescribing 
Information: Drugs Used in Parasitic Diseases(23,24) and, on the other hand, with 















· 𝐴𝑑𝑢𝑙𝑡 𝑑𝑜𝑠𝑒 
 
Fried’s Rule is a modification of the Clark’s Rule (used for children from 2 to 7 
years old) that can be used for newborns and infants. This method is based on the 
age and maturational development. Provided that age cannot be the only variable 
taken into account for dose estimation(25), these formulas are not commonly used 
but may be useful when referenced doses are not available.  
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For the dose calculation with BSA Method, the percentile 50th BSA of boy values in 
the WHO growth charts(21) (for ages 0.5 months and 12.5 months) and Centers 
for Disease Control and Prevention (CDC) charts(22) (for age 7 years) were used. 
For referenced drug doses expressed in mg/kg, the 50th percentile weight as in the 
calculation of BSA was used to calculate the total dose. 
Since three different methods were used to calculate the dose in the three 
paediatric populations, the obtained values were compared to the referenced dose 
when available. Referenced dose is assumed to be the gold standard as it is based 
on clinical use and thus in adequate risk/benefit ratio. 
Drug solubility data (mg/mL) were obtained from several bibliographic sources. 
Nevertheless, in order to obtain a solubility classification the solubility values were 
obtained from “The International Pharmacopoeia” (26) and “Merck Index”(27). 
The most conservative data of solubility were used. When specific solubility values 
were not available, a value was assigned according to Table 1. Solubility values in 
the range of physiological pH’s were considered for classification in the case of 
ionizable compounds (weak acid or bases). The pH fluctuation that occurs in the 
gastrointestinal tract with paediatric development since birth(4,28,29) is in our 
view, one of the principle factors that can cause variation in drug absorption and 
clinical efficacy. For instance, gastric pH in the newborn is neutral (pH 6-8) at 
birth. During the first 24-48 hours of life, it descends to adult values (pH 1-3) 
thanks to an overproduction of gastric acid and then ascends back to values close 
This article is protected by copyright. All rights reserved.
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to neutrality for 20-30 days(28,29). From that moment, pH progressively descends 
until reaching adult levels by 2 years of age(4).  
These variations in pH may influence ionizable drugs, affecting absorption by 
changes in the relative amount of unionized drug available(30). Lower levels of 
gastric pH might be involved in the enhanced bioavailability of weak bases by 
increasing their solubility(31,32). Conversely, weak acids at a more acid 
environment are less ionized, consequently, dissolution is decreased and 




Permeability data was considered as if drugs were transported across biological 
membranes by passive transcellular diffusion, even though carrier-mediated 
mechanisms might coexist(33). Log P (n-octanol/water partition coefficient) 
values were obtained from Chemicalize(34), an online platform for chemical 
calculations.  
The classification was based on the relationship between human intestinal 
permeabilities and log P values. As other authors(35–37), metoprolol was selected 
as the reference compound for permeability because it is known to be absorbed up 
to 95%. Thereby, drugs with estimated log P values greater than or equal to 1.76 
were rated as high-permeability drug and, contrariwise, drug values lower than 
1.76 were rated as low-permeability drugs. 










Classification of Drug Solubility 
The estimated parameters for the three paediatric subgroups to all six NTDs drug 
to calculate the solubility are indicated in Table 2 
 
Drugs with estimated dose number of ≤1 were classified as high-solubility drugs, 
conversely, drugs with estimated dose number of >1 were classified as low-
solubility drugs. 
All the reported values of solubility of the studied NTD drugs are summarized in 
Table 3. 
 




Classification of Drug Permeability 
 
The data found in the literature was used to propose a provisional classification for 
each compound according paediatric characteristics (Table 4). 
 
Albendazole pBCS Provisional Classification 
Albendazole is a benzimidazole anthelmintic drug particularly active in 
echinococcosis. It has a very high affinity for the beta-tubulin of the parasite.  
Albendazole binds with beta-tubulin units of the parasite inhibiting their 
polymerization into microtubules and, consequently, disrupts the absorption of 
nutrients by the parasite(38).  
Albendazole is a weak base at physiological pH range with a strongest basic pKa of 
4.2 and a minimum estimated solubility value at pH 6(34).  
Practically insoluble in water, a solubility of 0.01 mg/mL was assigned that is 
similar in comparison with the other experimental or estimated values from 
literature (Table 3). 
It was classified as a high-permeability drug with a log P of 3.2. 
Safety and efficacy of oral albendazole have not been established in children up to 
two years. Therefore, M0p of neonates and infants were estimated by clinical 
formulas in order to have a provisional estimation of the dose in those stages. For 
children over 2 years old, referenced M0p=400 mg(23) was used. 




Table 4 lists M0p for every dosage, the estimated paediatric dose number and pBCS 
classification for each defined paediatric stage. 
 
 
Benznidazole pBCS Provisional Classification 
Benznidazole is a 2-nitroimidazole derivative which has an inhibitory effect on 
protein synthesis and ribonucleic acid synthesis in Trypanosoma cruzi cells, it is 
used in Chagas disease(39) at a paediatric dose of 5 mg/kg(23). 
Benznidazole is a weak base at physiological pH range (strongest basic pKa of 
4.21). At pH 3.2 is the minimum estimated solubility value(34). 
Practically insoluble according to WHO Pharmacopoeia(26). A solubility of 0.01 
mg/mL was chosen that in comparison of the other values of Table 3 is a 
conservative estimate. 
It was classified as a low-permeability drug with a log P of 1.64. 
Table 4 lists M0p for every dosage methods, the estimated paediatric dose number 
and pBCS classification for each defined paediatric stage. 
 
 
Ivermectin pBCS Provisional Classification 
Ivermectin is a semisynthetic acaracide drug, which is produced by fermentation 
by using Streptomyces avermitilis. It binds selectively and with high affinity to 
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glutamate-gated chloride ion channels in invertebrate muscle and nerve cells of 
the microfilaria. This binding causes an increase in the permeability of the cell 
membrane to chloride ions and results in hyperpolarization of the cell, leading to 
paralysis and death of the parasite(40). 
Safety and efficacy of oral ivermectin have not been established in paediatric 
patients weighing less than 15 kg. Because of this, the referenced dose of 200 
μg/kg(23) was used only for children, the group with a weight greater than 15 kg 
in the 50th percentile. 
Ivermectin is a neutral base at physiological environment and its solubility do not 
change with pH variations(34) 
The WHO Pharmacopoeia does not collect ivermectin data. The Merck Index(27) 
provides a solubility data of 0.004 mg/mL (Table 3). 
It was classified as a high-permeability drug with a log P of 5.83. 
 Table 4 lists M0p for every dosage, the estimated paediatric dose number and pBCS 
classification for each defined paediatric stage. 
 
Nifurtimox pBCS Provisional Classification 
Nifurtimox is a 5-nitrofuran derivative whose mechanism of action appears to be 
related to its metabolism via partial reduction to chemically reactive radicals that 
cause production of toxic reduced products of oxygen(41). It is mainly used to 
treat Chagas disease in early stages at a paediatric dose of 5 mg/kg(23). 
This article is protected by copyright. All rights reserved.
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Nifurtimox is a weak base at physiological pH range with a strongest basic pKa of 
0.34 and a minimum estimated solubility value at pH 3. 
The most conservative solubility definition (Table 3) was practically insoluble in 
water(26). Thus, a solubility of 0.01 mg/mL was considered. 
It was assigned to the group of low-permeability drugs with a log P of -0.27. 
Table 4 lists M0p for every dosage method, the estimated paediatric dose number 
and pBCS classification for each defined paediatric stage. 
 
Praziquantel pBCS Provisional Classification 
Praziquantel is used to treat cestodiasis. It produces a change in the calcium 
permeability of the parasite membranes, causing serious injury to the tegument, 
massive contraction, paralysis, disruption of metabolism and death(42).  
Safety and efficacy of oral praziquantel in children less than 4 years old has not 
been established. Consequently, M0p of neonates and infants was estimated by 
clinical formulas. For children stage we used M0p=25mg/kg(23). 
Praziquantel is a neutral base and therefore, the solubility does not change at 
physiological pH range. 
The most conservative solubility definition was very slightly soluble in water(26), 
a solubility of 0.1 mg/mL was assigned. The chosen value was similar to reported 
values but greater than the estimated value in the most disadvantaged pH 
condition (Table 3) 
It was classified as high-permeability drug with a log P of 2.3. 
This article is protected by copyright. All rights reserved.
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Table 4 lists M0p for every dosage method, the estimated paediatric dose number 
and pBCS classification for each defined paediatric stage. 
 
Proguanil pBCS Provisional Classification 
Proguanil is used for prophylaxis against Plasmodium falciparum and Plasmodium 
vivax. Proguanil itself is a prodrug and must be metabolized to cycloguanil for 
antimalarial activity. Cycloguanil inhibits nucleic acid synthesis by inhibiting 
plasmodial dihydrofolate reductase(43). 
Referenced doses for proguanil are: 25 mg for neonates, 50 mg for infants and 100 
mg for children(23). 
Proguanil is a neutral base in physiological environment consequently its solubility 
is not affected. 
The most conservative solubility definition was slightly soluble in water(26), a 
solubility of 1 mg/mL was selected (Table 3). 
It was classified as high-permeability drug with a log P of 2.38. 
Table 4 lists M0p for every dosage method, the estimated paediatric dose number 
and pBCS classification for each defined paediatric stage. 
  





The main reason for developing a pBCS is to encourage the design of specific NTD 
drugs medications for paediatric population. Secondly, the risks of reformulating 
adult medication for administration to children could be predicted based on the 
changes of classification between adults and children. Finally, pBCS might help to 
estimate the risk of non-bioequivalence across different compounding 




In many cases when paediatric formulation is not available, the demand is met by 
compounding preparations, as viscous suspensions formulated from commercial 
adult tablets or capsules by incorporating other excipients(4). This process of 
adapting the formulation can modify BCS parameters, especially the solubility. 
Excipients are not necessarily inert substances for children as is often assumed, 
and their use has resulted in severe adverse effects in children(44). Excipients 
used in adult medicines cannot always be supposed to have the same effect in 
children. Furthermore, effects may differ between different age groups because of 
age-related changes. For example, children from earlier stages may not be able to 
metabolize or eliminate them as an adult(45,46). Therefore, the selection of 
excipients is an important stage in paediatric formulation development(46) and it 
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is always better to use the minimal amount and number of excipients(5). pBCS can 
be used as a tool to predict the complexity of infant formulation, as pediatric Class I 
and III compounds (i.e high solubility) are expected to need less excipients while 
Class II/IV may need for instance solubilizing agents. 
The flavour profile will be closely related to therapeutic non-compliance, making 
organoleptic additives and bitter taste-masking technologies very important (47). 
The unanswered question is whether the physical changes associated with these 
technologies affect or not to the drug release compared with a conventional adult 
formulation and how this comparison could be made on a meaningful in vitro test 
representing the children gastrointestinal tract. Again the paediatric BCS could be 
envisaged as a tool to decipher whether a conventional dissolution apparatus 
could be used to predict and compare pediatric products performance, as in adult 
BCS Class I/III or whether new dissolution devices reflecting children pH profiles, 




Our objective was to classify six NTDs drugs into a provisional pBCS. This 
classification is defined as provisional, since absolute human permeability data are 
not available for the studied age stages and the doses and volume used are also 
estimations. It is known that intestinal permeability decreases progressively 
during the first week since birth, when is described to be high(28). But drug 
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permeability within paediatric populations is under-researched. Therefore, log P 
values were used to perform a provisional permeability classification as 
lipophilicity of the drug is one of the main determinants of the drug membrane 
permeability by passive diffusion. However, this factor is one of the main 
limitations of the present study.  Classification of drug permeability is based on 
comparison with metoprolol, as its fraction absorbed in adults is higher than 90%. 
If Metoprolol absorption is similar in paediatric population is adequate to use this 
compound as a cut off for provisional classification but the best model compound 




As well as permeability, a limitation for performing the pBCS classification is the 
availability of experimental solubility values.  
Intestinal absorption of drugs depends directly on the dissolution of the compound 
and the subsequent passage through the gastrointestinal mucosa. The solubility of 
a compound in physiological fluids is an essential requirement for it to become 
absorbed since only dissolved drugs can be absorbed(28). 
 
Drug dissolution depends on its physicochemical and physiological 
characteristics(29). Age-related changes in the composition of gastrointestinal 
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fluids particularly pH and will result in changes in drug solubility, gastrointestinal 
dissolution and absorption(48).  
 
pH, Solubility and Absorption Age Differences in Paediatric Population 
 
Albendazole, benznidazole and nifurtimox are among the drugs selected for this 
study whose solubility is affected in the acid pH range (pH 1-6)(34). We can 
assume that absorption will be influenced by growth due to changes in 
gastrointestinal pH that occur from birth to approximately 2 years of age(28,32).  
If the solubility data used to calculate the provisional pBCS is analysed and 
compared with reported values of water solubility (Table 3), it can be seen that, in 
all of the drugs, the most conservative data has been used.  With respect to the 
estimated solubility by log S(34) in the most disadvantaged condition of the 
physiological pH range, there are many discrepancies with literature values. For 
example, the log S predicted values from Chemicalize are higher than literature 
reported values. The exceptions are albendazole and praziquantel for which 
predicted values are in accordance with literature values. The estimated solubility 
data of ivermectin and proguanil were unexpectedly high compared with the 
reported values, so the predictions were not considered reliable(34). 
 
Paediatric Reference Volume 
 
This article is protected by copyright. All rights reserved.
 
 25 
Another limitation that we have found for pBCS classification limits definition is 
the determination of the volume of administration. In adults it is determined in 
250 mL of water(19), but not for the paediatric population or in its stages. As 
discussed by Batchelor et al. (49), the pBCS working group used a provisional 
estimate of 25 mL as reference volume for each paediatric stages(5). Currently in 
the literature there are authors who choose to calculate the relative volume based 
on the volume of gastric fluids and extrapolate it to the 250 mL used for 
adults(50,51), for this case the range of volumes goes from 13.2 ml in neonates to 
56.6 ml up to 3 years old. Another option is to estimate the administered volume 
based on the extrapolated BSA of each development stage from the volume 
administered in adults(52). BSA extrapolation option lead to the higher volume 
estimations thus is a less conservative option. For the present work these different 
volumes only would affect to the solubility class of proguanil in neonates and 
infants with the referenced doses that would be classified as low solubility with 




The lack of referenced doses 
 
The fourth limitation we found is the lack of referenced doses, mainly in neonates 
and infants. Albendazole, ivermectin and praziquantel do not have referenced 
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doses for these stages and the only option to classify them is via clinical empirical 
formulas. Large differences have been detected between calculated dosages by 
Clark’s and Fried’s rules and BSA rule. Given this assumption, when no referenced 
doses are available, we may be overdosing or underdosing. For example, in the 
case of benznidazole in infants and children (Table 4), Fried's Rule calculated dose 
is much lower than BSA Rule one, which is approximately half of the referenced 
dose. In the case of nifurtimox, both Fried's Rule and Clark's Rule doses are lower 
that the referenced. In the case of proguanil, BSA Rule dose is twice the referenced 
one. 
The only cases in which the referenced dose and the dose calculated with Clark's 
Rule are very similar were in the population of children with the drugs ivermectin 
and praziquantel (Table 4).  
The notable differences between doses for the same stage may lead to the 
classification of the drug into a different group of pBCS according to the selected 
dosage. For example, using Fried's Rule for benznidazole leads to a pBCS class 3, 
while the other dosages result in a pBCS class 4 (Table 4 ). These variations can 
also be observed for ivermectin and proguanil. Note that Dop values are very close 
to 1 in the case of benznidazole obtained with Fried's Rule for neonates and 
proguanil obtained with Clark's Rule for children. 
 
 
Provisional pBCS Classification 




Regarding permeability, four of the six compounds were classified as highly 
permeable (albendazole, ivermectin, praziquantel and proguanil). In terms of 
solubility (based on the paediatric dose number), low-solubility classification 
predominates. None of the drugs were classified in pBCS class 3 and only proguanil 
was classified in pBCS class 1 with some dosages. 
Table 4 summarizes the different paediatric classifications in comparison with 
regarding adult classification. 
 
Benznidazole dose with Fried’s Rule is assigned to a different class (pBCS class 3) 
(Table 4). The other example is ivermectin in which M0p by Fried’s rule is so small 
compared to the others, that there is a change in the solubility classification from 
low to high solubility. 
Albendazole, nifurtimox and praziquantel maintain the same pBCS classification 
for their different dosages at any stage and with respect to adult BCS classification. 
Proguanil is the only one that presents changes in all stages (Table 4). Taking as 
the most relevant dose the referenced one, it can be observed that there is a switch 
from Class 2 in aBCS to Class 1 in pBCS in the three-paediatric stages. There is an 
improvement in solubility that makes it to be classified to a more favourable class. 
This change would decrease the formulation development risks and it would ease 
the demonstration of bioequivalence among different formulations but 
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additionally could lead to a higher fraction absorbed in children and thus a higher 
exposure. 
Which are the implications for compounding pharmaceutical preparations with 
these drugs? Being class 2 or 4 drugs it means solubility and dissolution are 
important factors affecting fraction absorbed and absorption rate. Excipients and 
dosage form may change dissolution rate and in consequence harmonized 
formulations would be desirable to ensure the same performance in different 
clinical units of hospitals. pBCS can be used as a tool to identify when formulation 
could be critical to ensure performance similar to the adult formulation and 
similarity across compounded formulas but as we have pointed out in this study 
there is a need to increase our knowledge of children gastrointestinal system in 









In summary, provisional pBCS classification of these six drugs shows potential 
changes in the limiting factors in oral absorption in paediatrics compared to the 
adult population. This valuable information could serve as a formulation tool 
during paediatric development and to minimize the potential risks when 
developing formulations for paediatric use by pharmaceutical compounding. The 
need of standardization of these formulations would be higher in those 
unfavourable classification changes from adult BCS to paediatric BCS as for 
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Parts of solvent 
required for one 






Very soluble (vs) <1 >1000 1000 
Freely soluble (fs) from 1 to 10 100-1000 100 
Soluble (s) from 10 to 30 33-100 33 
Sparingly soluble (sps) from 30 to 100 10-33 10 
Slightly soluble (ss) from 100 to 1000 1-10 1 
Very slightly soluble (vss) from 1000 to 10000 0,1-1 0,1 
Practically insoluble (pi) >10000 <0,1 0,01 









P50th Weight (kg) 
(21,22) 3.7 9.8 23 
P50th Length (cm) 
(21,22) 52.5 77.0 122.0 
BSA (m2) 0.23 0.46 0.88 
Normalized V0p (mL) 33.57 66.16 127.58 
Table 2 Shared parameters to obtain pBCS classification 
  





Reported values (mg/mL) 
Estimated solubility by logS in the 
most unfavourable condition of the 
physiological pH range (mg/mL) (34) 




pi in water(26) 
pi in water(27) 
0.01 (in water) (53) 
0.011 (logS at pH 6) 0.01 
Benznidazole 
pi in water(26) 
0.4 (35) 
0.04 (in buffer at pH 7.4)(54) 
0.237 (in water at 25ºC) (55) 
0.236 (in simulated gastric fluid at pH 1.2) (55) 
0.244 (in simulated enteric fluid at pH 6.8) (55) 
1.404 (logS at pH 3.2) 0.01 
Ivermectin 
0.004 (in water)(27,35) 
0.0007 (in simulated intestinal fluid at pH 6.5)(56) 
0.12 (in fasted-state simulated intestinal fluid at pH 6.5)(56) 
158,341.953 (logS at pH range 1-6) 0.004 
Nifurtimox 
pi in water(26) 
s in water(27) 
0.158 (logS at pH 3) 0.01 
Praziquantel vss in water(26) 0.008 (logS at pH range 1-6) 0.1 
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0.4 (in water)(27,35) 
0.215 (in water at 37ºC)(57) 
Proguanil 
ss in water(26) 
0.156 (in water)(58) 
253.73 (logS at pH range 1-6) 1 
Table 3 Solubility values of selected NTD drugs. Drugs whose solubility values do not vary in the range of physiological pH are given in italics. *Values to be taken with 
caution as they differ greatly from the experimental ones. Abbreviations: pi, practically insoluble; vss, very slightly soluble; ss, slightly soluble; s, soluble.













Fr-R BSA-R Ref Fr-R BSA-R Ref Cr-R BSA-R Ref 
Albendazole          
M0p 1.33 53.71 - 33.33 105.86 - 135.22 204.13 400.00 
Dop 3.97 160.00 - 50.38 160.00 - 105.98 160.00 313.53 
Permeability High-permeability drug 
pBCS 2 2 - 2 2 - 2 2 2 
aBCS 2 
 BCS Class 2: Absorption limited by solubility and dissolution. Pancreatic and biliary development 
with age will improve absorption, formulation in a digestible lipid vehicle will improve oral 
absorption 
Benznidazole          
M0p 0.33 13.43 18.50 8.33 26.46 49.00 33.80 51.03 115.00 
Dop 0.99 40.00 55.11 12.60 40.00 74.06 26.50 40.00 90.14 
Permeability Low-permeability drug 
pBCS 3 4 4 4 4 4 4 4 4 
aBCS     4     
 BCS Class 3-4 depending on dose. Low permeability and low solubility at high dose. More frequent 
dosing of solubilised drug will improve absorption 
Ivermectin          
M0p 0.05 1.88 - 1.16 3.71 - 4.73 7.14 4.6 
Dop 0.34 14.00 - 4.41 14.00 - 9.27 14.00 9.01 
Permeability High-permeability drug 
pBCS 1 2 - 2 2 - 2 2 2 
aBCS 2 
 BCS Class 2 (1 at lowest doses. May be Class 4 due to high molecular weight. Digestible lipidic 
solubilisation vehicle would improve absorption. 
Nifurtimox          
M0p 0.83 33.57 18.50 20.83 66.16 49.00 84.51 127.58 115.00 
Dop 2.48 100.00 55.11 31.49 100.00 74.06 66.24 100.00 90.14 
Permeability Low-permeability drug 
pBCS 4 4 4 4 4 4 4 4 4 
aBCS 4 
 BCS Class 4 
Praziquantel          
M0p 5.83 234.97 - 145.83 463.13 - 591.57 893.07 575.00 
Dop 1.73 70.00 - 22.04 70.00 - 46.37 70.00 45.07 
Permeability High-permeability drug 
pBCS 2 2 - 2 2 - 2 2 2 
aBCS 2 
 BCS Class 2. Absorption limited by solubility and dissolution, digestible lipid vehicles aid absorption. 







xii.            Word count (excluding the title page, summary, references, legends 




Proguanil          
M0p 1.33 53.71 25.00 33.33 105.86 50.00 135.22 204.13 100.00 
Dop 0.04 1.60 0.74 0.50 1.60 0.76 1.06 1.60 0.78 
Permeability High-permeability drug 
pBCS 1 2 1 1 2 1 2 2 1 
aBCS 2 
 BCS Class 2-1: high to low dose. Absorption of high doses aided by lipid vehicle. 
Table 4 Provisional pBCS Classification of the six selected drugs with formulation recommendations. 1Drugs with the 
same pBCS Classification as adult BCS is given in italics. 2Drugs in bold italics indicate some variation in pBCS 
classification to the adult BCS. 3Drugs in bold indicate changes in pBCS Classification in all stages. 4Abbreviations: Fr-R, 
Fried’s Rule dosage; BSA-R, Body Surface Area Rule dosage; Ref, Referenced dose dosage; aBCS, adult BCS 
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